Omega-3 GABA Derivatives Enhance Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GABA derivatives struggle to effectively cross the blood-brain barrier and provide sustained therapeutic effects for neurological conditions such as neuropathic pain, epilepsy, and Alzheimer's disease, due to limitations in their pharmacological properties and ability to inhibit GABA-degrading enzymes.
Innovation Solution
Development of omega-3 polyunsaturated fatty acid derivatives of GABA, where omega-3 acids are substituted at the central 3-position carbon, forming unique compounds with superior blood-brain barrier crossing ability and potential for irreversible inhibition of GABA-T, leading to prolonged GABA brain levels and multiple beneficial modes of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional GABA derivatives are used, then they can provide some therapeutic effect, but they struggle to effectively cross the blood-brain barrier and provide sustained therapeutic effects
Solution Approach 1:
The patent modifies the chemical structure of GABA derivatives by substituting the central 3-position carbon with omega-3 polyunsaturated fatty acid chains of varying lengths and unsaturation degrees. This parameter change in molecular structure enhances lipophilicity and enables irreversible inhibition of GABA-T enzyme, thereby improving blood-brain barrier crossing ability and prolonging therapeutic effect duration.
Solution Approach 2:
The invention creates composite molecular structures by combining GABA core structure with omega-3 fatty acid chains. This composite approach integrates the neuroactive properties of GABA with the membrane-permeable characteristics of polyunsaturated fatty acids, achieving both effective BBB penetration and sustained action through dual mechanisms of GABA receptor modulation and GABA-T inhibition.
2Speed
If GABA derivatives are designed to cross the blood-brain barrier more effectively, then BBB crossing ability is improved, but the ability to provide sustained therapeutic effects through enzyme inhibition may be compromised
Solution Approach 1:
The omega-3 GABA derivatives are designed to perform multiple functions simultaneously: they act as GABA analogs that can cross the blood-brain barrier and modulate GABA receptors, while also serving as irreversible inhibitors of the GABA-T enzyme. This multi-functionality ensures both rapid BBB penetration and prolonged therapeutic effect through sustained elevation of brain GABA levels.
Solution Approach 2:
The irreversible inhibition of GABA-T by the omega-3 GABA derivatives creates a continuous useful action by preventing GABA degradation over extended periods. This continuous enzyme inhibition maintains elevated GABA levels in the brain, ensuring sustained therapeutic effects without requiring frequent dosing.
3Ease of operation
If existing GABA analogs like gabapentin and pregabalin are used, then they facilitate diffusion across the BBB through L-amino acid transporter, but they lack irreversible inhibition of GABA-T enzyme
Solution Approach 1:
The patent merges two previously separate mechanisms into a single compound: the L-amino acid transporter-mediated BBB transport mechanism (known from gabapentin and pregabalin) and the irreversible GABA-T inhibition mechanism (known from vigabatrin). The omega-3 GABA derivatives utilize both mechanisms simultaneously, enhancing BBB crossing while providing sustained action through enzyme inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These omega-3 GABA derivatives demonstrate enhanced BBB crossing ability and prolonged biological response, offering improved treatment options for neuropathic pain, epilepsy, anxiety, depression, and Alzheimer's disease, with potential for sustained GABA levels and enhanced therapeutic effects compared to existing analogs like pregabalin.
Implementation Method 1
All these compounds are lipophilic analogs of GABA, substituted at the central 3rd carbon of GABA to facilitate diffusion across the BBB
Implementation Method 2
The vinyl group in vigabatrin participates in the irreversible inhibition of the enzyme GABA-T, and sustains higher brain levels of GABA. It is also possible that one or more conjugated double bonds in omega-3 oils may participate in irreversible inhibition of the enzyme γ-aminobutyric acid α-oxoglutarate transaminase (GABA-T)
Data Source
AI summary
The present invention relates to omegabalins, which are GABA derivatives of omega-3 fatty acids, and their use in pharmaceutically-acceptable formulations for treating neuropathic pain, fibromyalgia, epilepsy, anxiety, depression, insomnia, Alzheimer's disease, and other neurological conditions.